{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:56Z","timestamp":1788822596390,"version":"build-2803163510"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Enara Bio Limited Magdalen Centre, The Oxford Science Park 1 Robert Robinson Avenue, Oxford, OX4 4GA, UK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02961-5","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:02:21Z","timestamp":1788822141000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2475-6526","authenticated-orcid":false,"given":"Thomas Morgan","family":"Hulen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Douglas","family":"Crowther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke Alexander","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawez","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimilia","family":"Schina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Donia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-9605","authenticated-orcid":false,"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-2647","authenticated-orcid":false,"given":"\u00d6zcan","family":"Met","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"2961_CR1","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2961_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2020-000668","volume":"8","author":"TH Borch","year":"2020","unstructured":"Borch, T. H. et al. Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J. Immunother. Cancer 8, 1\u20137 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"2961_CR3","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"2961_CR4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","volume":"614","author":"L Labanieh","year":"2023","unstructured":"Labanieh, L. & Mackall, C. L. CAR immune cells: Design principles, resistance and the next generation. Nature 614, 635\u2013648 (2023).","journal-title":"Nature"},{"key":"2961_CR5","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.tranon.2022.101459","volume":"22","author":"PA Atilla","year":"2022","unstructured":"Atilla, P. A. & Atilla, E. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. Transl. Oncol. 22, 101459 (2022).","journal-title":"Transl. Oncol."},{"key":"2961_CR6","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-018-0040-8","volume":"24","author":"N Zacharakis","year":"2018","unstructured":"Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat. Med. 24, 724\u2013730 (2018).","journal-title":"Nat. Med."},{"key":"2961_CR7","doi-asserted-by":"publisher","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","volume":"6","author":"C Aggarwal","year":"2023","unstructured":"Aggarwal, C. et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Netw. Open 6, e2311181 (2023).","journal-title":"JAMA Netw. Open"},{"key":"2961_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"2961_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nri.2016.27","volume":"16","author":"G Kassiotis","year":"2016","unstructured":"Kassiotis, G. & Stoye, J. P. Immune responses to endogenous retroelements: taking the bad with the good. Nat. Rev. Immunol. 16, 207\u2013219 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"2961_CR10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","volume":"6","author":"A Apavaloaei","year":"2025","unstructured":"Apavaloaei, A. et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nat. Cancer 6, 1419\u20131437 (2025).","journal-title":"Nat. Cancer"},{"key":"2961_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14968-9","volume":"11","author":"C Chong","year":"2020","unstructured":"Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).","journal-title":"Nat. Commun."},{"key":"2961_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.yexcr.2008.12.023","volume":"315","author":"A Serafino","year":"2009","unstructured":"Serafino, A. et al. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation. Exp. Cell Res. 315, 849\u2013862 (2009).","journal-title":"Exp. Cell Res."},{"key":"2961_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41587-021-01021-3","volume":"40","author":"T Ouspenskaia","year":"2022","unstructured":"Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. 40, 209\u2013217 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2961_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2326-6066.CIR-22-0621","volume":"11","author":"G Bedran","year":"2023","unstructured":"Bedran, G. et al. The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I\u2013Associated Peptides. Cancer Immunol. Res. 11, 742\u2013762 (2023).","journal-title":"Cancer Immunol. Res."},{"key":"2961_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-024-03660-y","volume":"11","author":"Y Cai","year":"2024","unstructured":"Cai, Y. et al. MHC-I-presented non-canonical antigens expand the cancer immunotherapy targets in acute myeloid leukemia. Sci. Data 11, 831 (2024).","journal-title":"Sci. Data"},{"key":"2961_CR16","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1101\/gr.248922.119","volume":"29","author":"J Attig","year":"2019","unstructured":"Attig, J. et al. LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly. Genome Res 29, 1578\u20131590 (2019).","journal-title":"Genome Res"},{"key":"2961_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41587-025-02701-0","volume":"44","author":"C Zhu","year":"2026","unstructured":"Zhu, C. et al. Identification of non-canonical peptides with moPepGen. Nat. Biotechnol. 44, 568\u2013573 (2026).","journal-title":"Nat. Biotechnol."},{"key":"2961_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adv6445","volume":"11","author":"Y Cai","year":"2025","unstructured":"Cai, Y. et al. Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Sci. Adv. 11, eadv6445 (2025).","journal-title":"Sci. Adv."},{"key":"2961_CR19","doi-asserted-by":"publisher","first-page":"e010099","DOI":"10.1136\/jitc-2024-010099","volume":"13","author":"P Bonaventura","year":"2025","unstructured":"Bonaventura, P. et al. HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer. J. Immunother. Cancer 13, e010099 (2025).","journal-title":"J. Immunother. Cancer"},{"key":"2961_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj3671","volume":"8","author":"P Bonaventura","year":"2022","unstructured":"Bonaventura, P. et al. Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci. Adv. 8, eabj3671 (2022).","journal-title":"Sci. Adv."},{"key":"2961_CR21","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2021","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res 48, W449\u2013W454 (2021).","journal-title":"Nucleic Acids Res"},{"key":"2961_CR22","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41591-025-03650-6","volume":"31","author":"M Wermke","year":"2025","unstructured":"Wermke, M. et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 31, 2365\u20132374 (2025).","journal-title":"Nat. Med."},{"key":"2961_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","volume":"29","author":"DS Hong","year":"2023","unstructured":"Hong, D. S. et al. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat. Med. 29, 104\u2013114 (2023).","journal-title":"Nat. Med."},{"key":"2961_CR24","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1038\/s41467-022-32811-1","volume":"13","author":"A Poole","year":"2022","unstructured":"Poole, A. et al. Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen. Nat. Commun. 13, 5333 (2022).","journal-title":"Nat. Commun."},{"key":"2961_CR25","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2961_CR26","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","volume":"5","author":"BJ Cameron","year":"2013","unstructured":"Cameron, B. J. et al. Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103 (2013).","journal-title":"Sci. Transl. Med."},{"key":"2961_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55420-6","volume":"16","author":"T Kuilman","year":"2025","unstructured":"Kuilman, T. et al. Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. Nat. Commun. 16, 649 (2025).","journal-title":"Nat. Commun."},{"key":"2961_CR28","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-22-0290","volume":"82","author":"M Chen","year":"2022","unstructured":"Chen, M. et al. Ancient human endogenous retroviruses contribute to genetic evolution and regulate cancer cell type\u2013specific gene expression. Cancer Res 82, 3457\u20133473 (2022).","journal-title":"Cancer Res"},{"key":"2961_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/apm.12478","volume":"124","author":"F Li","year":"2016","unstructured":"Li, F. & Karlsson, H. Expression and regulation of human endogenous retrovirus W elements. APMIS 124, 52\u201366 (2016).","journal-title":"APMIS"},{"key":"2961_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/gcc.20751","volume":"49","author":"S Stengel","year":"2010","unstructured":"Stengel, S., Fiebig, U., Kurth, R. & Denner, J. Regulation of human endogenous retrovirus-K expression in melanomas by CpG methylation. Genes Chromosom. Cancer 49, 401\u2013411 (2010).","journal-title":"Genes Chromosom. Cancer"},{"key":"2961_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2090-3","volume":"10","author":"W Luan","year":"2019","unstructured":"Luan, W. et al. Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p\/AP1S2 axis. Cell Death Dis. 10, 855 (2019).","journal-title":"Cell Death Dis."},{"key":"2961_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03387-3","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Long noncoding RNA LINC00518 induces radioresistance by regulating glycolysis through an miR-33a-3p\/HIF-1\u03b1 negative feedback loop in melanoma. Cell Death Dis. 12, 246 (2021).","journal-title":"Cell Death Dis."},{"key":"2961_CR33","doi-asserted-by":"publisher","first-page":"1419576","DOI":"10.3389\/fimmu.2024.1419576","volume":"15","author":"Q Yi","year":"2024","unstructured":"Yi, Q. et al. LINC00518: a key player in tumor progression and clinical outcomes. Front. Immunol. 15, 1419576 (2024).","journal-title":"Front. Immunol."},{"key":"2961_CR34","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois, D. et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961\u2013973 (2015).","journal-title":"Cell"},{"key":"2961_CR35","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli, K. B. et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974\u2013986 (2015).","journal-title":"Cell"},{"key":"2961_CR36","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ng.3889","volume":"49","author":"D Brocks","year":"2017","unstructured":"Brocks, D. et al. DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats. Nat. Genet. 49, 1052\u20131060 (2017).","journal-title":"Nat. Genet."},{"key":"2961_CR37","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1098\/rstb.2016.0277","volume":"372","author":"G Kassiotis","year":"2017","unstructured":"Kassiotis, G. & Stoye, J. P. Making a virtue of necessity: The pleiotropic role of human endogenous retroviruses in cancer. Philos. Trans. R. Soc. B. Biol. Sci. 372, 1732 (2017).","journal-title":"Philos. Trans. R. Soc. B. Biol. Sci."},{"key":"2961_CR38","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen, G. M. et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science 378, eaba1624 (2022).","journal-title":"Science"},{"key":"2961_CR39","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"2961_CR40","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","volume":"122","author":"GP Linette","year":"2013","unstructured":"Linette, G. P. et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122, 863\u2013871 (2013).","journal-title":"Blood"},{"key":"2961_CR41","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A. et al. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"2961_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1365-3083.2011.02640.x","volume":"75","author":"M Donia","year":"2012","unstructured":"Donia, M. et al. Characterization and comparison of \u2018standard\u2019 and \u2018young\u2019 tumour-infiltrating lymphocytes for adoptive cell therapy at a danish translational research institution. Scand. J. Immunol. 75, 157\u2013167 (2012).","journal-title":"Scand. J. Immunol."},{"key":"2961_CR43","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","volume":"22","author":"R Andersen","year":"2016","unstructured":"Andersen, R. et al. Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated il2 regimen. Clin. Cancer Res. 22, 3734\u20133745 (2016).","journal-title":"Clin. Cancer Res."},{"key":"2961_CR44","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast and bias-aware quantification of transcript expression. Nat. Methods 14, 417\u2013419 (2017).","journal-title":"Nat. Methods"},{"key":"2961_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01460-0","volume":"8","author":"M Lauss","year":"2017","unstructured":"Lauss, M. et al. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat. Commun. 8, 1738 (2017).","journal-title":"Nat. Commun."},{"key":"2961_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-019-2809-2","volume":"20","author":"J Jo","year":"2019","unstructured":"Jo, J. et al. Conventionally used reference genes are not outstanding for normalization of gene expression in human cancer research. BMC Bioinforma. 20, 245 (2019).","journal-title":"BMC Bioinforma."},{"key":"2961_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"2961_CR48","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-61779-325-7_15","volume":"792","author":"Z Moodie","year":"2012","unstructured":"Moodie, Z., Price, L., Janetzki, S. & Britten, C. M. Response determination criteria for ELISPOT: Toward a standard that can be applied across laboratories. Methods Mol. Biol. 792, 185\u2013196 (2012).","journal-title":"Methods Mol. Biol."},{"key":"2961_CR49","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"EF Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02961-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02961-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02961-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:02:22Z","timestamp":1788822142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02961-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2961"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02961-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Enara Bio contributed to the antigen discovery and validation experiments in this study. The authors declare that they have no financial, commercial, or professional affiliations with Enara Bio. M.D. has received proprietary data access from Bristol Myers Squibb and Genentech and is an advisor of Achilles Therapeutics. MHA is an advisor and shareholder at IO Biotech. I.M.S. has received honoraria for consultancies and lectures from Novartis, Roche, Merck, and Bristol Myers Squibb; a restricted research grant from Novartis; and financial support for attending symposia from Bristol Myers Squibb, Merck, Novartis, Pfizer, and Roche. \u00d6M reports grants from public funding sources to institution from the Danish Cancer Society, Novo Nordisk Foundation, and Independent Research Fund Denmark. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"370"}}